John W. Smither - 31 Aug 2023 Form 3 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Chief Financial Officer
Signature
/s/ Masaru Matsuda, Attorney-in-Fact for John W. Smither
Issuer symbol
ARQT
Transactions as of
31 Aug 2023
Net transactions value
$0
Form type
3
Filing time
05 Sep 2023, 21:36:53 UTC
Previous filing
22 Jun 2023
Next filing
13 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ARQT Common Stock 141,392 31 Aug 2023 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARQT Stock Option (right to buy) 31 Aug 2023 Common Stock 33,602 $1.68 Direct F2
holding ARQT Stock Option (right to buy) 31 Aug 2023 Common Stock 40,482 $1.68 Direct F2
holding ARQT Stock Option (right to buy) 31 Aug 2023 Common Stock 8,379 $27.61 Direct F2
holding ARQT Stock Option (right to buy) 31 Aug 2023 Common Stock 25,718 $32.44 Direct F2
holding ARQT Stock Option (right to buy) 31 Aug 2023 Common Stock 4,165 $6.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F2 This option is fully vested.

Remarks:

Exhibit 24 - Power of Attorney attached.